TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotech firm focused on novel cancer therapies targeting the tumour microenvironment, announced on Wednesday that it NOX-A12 GLORIA Phase 1/2 trial results will be presented at the European Society for Medical Oncology (ESMO) Congress in Barcelona from 13-17 September 2024.

The oral presentation will cover the dual inhibition of NOX-A12 and bevacizumab in glioblastoma, analyzed in the expansion arm of the GLORIA trial.

Dr Frank A. Giordano, Chair of the Department of Radiation Oncology at University Medical Center Mannheim, Germany, will present the findings during the mini oral session on CNS tumours on 15 September 2024 at 08.30 am CEST.

TME Pharma focuses on developing innovative therapies for aggressive cancers by targeting the tumor microenvironment and the cancer immunity cycle, aiming to dismantle tumour protection barriers and inhibit tumour repair.